Metilfenidato Mylan

Methylphenidate, the active ingredient in Metilfenidato Mylan, is a central nervous system stimulant presented as an oral tablet for oral use. It is prescribed for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Metilfenidato Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for regulated medicines.

Methylphenidate is used in the management of central nervous system disorders that affect attention and wakefulness. - Attention deficit hyperactivity disorder (ADHD) in children and adolescents: Improves concentration, reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (ADHD) in adults: Enhances focus and reduces distractibility. - Narcolepsy: Decreases excessive daytime sleepiness and improves alertness.

Methylphenidate may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea, abdominal discomfort. - Increased heart rate: mild tachycardia.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychiatric symptoms: new or worsening psychosis, mania, or severe anxiety. - Allergic reactions: rash, hives, or anaphylaxis.

When prescribing methylphenidate, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: screen for history of psychosis, bipolar disorder, or severe anxiety. - Growth monitoring: track height and weight in children during prolonged treatment. - Drug abuse potential: assess risk of misuse or dependence, especially in adolescents. - Concomitant medications: review for agents that may increase blood pressure or interact adversely. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methylphenidate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid co‑administration. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: methylphenidate may reduce their effectiveness, leading to uncontrolled blood pressure.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Anticonvulsants (e.g., carbamazepine): can lower methylphenidate plasma levels. - Proton pump inhibitors: may affect absorption, requiring monitoring.